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j.jtcvs.2012.09.048TABLE 1. Characteristics of patients treated with bivalirudin after cardiac surgery
Before
(2004-2006)
After
(2007-2010)
Thrombocytopenia 15.1%
463/3065
14.5%
476/3288
DTI use in patients with thrombocytopenia 17.5%
81/463
23.1%
110/476
HITTS (per decreased platelets) 4.3%
20/463
5.5%
26/476
HITTS (per total adult patients) 0.7%
20/3065
0.8%
26/3288
HITTS mortality 60.0%
12/20
23.0%
6/26
Thrombocytopenia is defined as a 50% decrease in platelets from preoperative baseline by 24 hours after cardiopul-
monary bypass. Mortality is defined as death within index admssion. DTI, Direct thrombin inhibitor; HITTS,
heparin-induced thrombocytopenia and thrombosis syndrome.AORTIC ARCH INTERRUPTION
WITHOUT DUCTUS
ARTERIOSUS AND NO
VENTRICULAR SEPTAL
DEFECT
To the Editor:
We read the interesting case report
by Cazavet and associates1 on ‘‘an in-
fant with a previously unrecorded type
of aortic arch interruption.’’ However,
similar types of aortic arch interrup-
tion without ductus arteriosus and
without ventricular septal defect, al-
though rare, have been previously de-
scribed since 1964.2-6 The common
features of these unusual patients
were the longevity up to adolescence
with no severe symptoms and
the presence of extensive collateral
circulation supplying the descending
aorta.2-6 Surgical treatment was also
reported in relation to the various
anatomic patterns.2-6 In the field of
pediatric cardiology, sometimes some
old scientific papers can represent
important sources of knowledge.
The interesting new aspect de-
scribed by Cazavet and associates1 is
the association with del 22q11 and
the relative embryogenetic implica-
tions that expand the spectrum
of cardiovascular defects of this
syndrome.
Carolina Putotto, MD
Marta Unolt, MD
Dario Marino, MD
Department of Pediatrics
‘‘La Sapienza’’ University
Rome, ItalyThe JournalReferences
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MANAGEMENT OF
HEPARIN-INDUCED
THROMBOCYTOPENIA IN
PATIENTS AFTER CARDIAC
SURGERY
To the Editor:
In a recent publication, Demma,
Paciullo, and Levy1 evaluated the rec-
ognition and treatment of heparin-
induced thrombocytopenia (HIT) in
patients after cardiothoracic surgery
using the direct thrombin inhibitor
(DTI) argatroban. We agree that the
detection and management of HIT in
patients who have had cardiac surgery
is of clinical importance, and we haveof Thoracic and Cardiovascular Surgeused a similar method of HIT identifi-
cation and treatment with the DTI
bivalirudin.
Our familiarity with the use of biva-
lirudin was heightened after our par-
ticipation in the CHOOSE-ON trial
published in 2007, which evaluated
the use of this DTI during cardiopul-
monary bypass in patients having car-
diac surgery.2 Since then, we have
standardized our method of identify-
ing HIT patients postoperatively and
treating them with bivalirudin. To de-
tect HIT, we use a method similar to
that of Demma, Paciullo, and Levy1
in which patients who score in the
moderate range on the 4-Ts schema3
are subjected to a platelet factor 4/
heparin immunoassay. Occasionally,
we will also confirm the diagnosis
with a serotonin release assay. To
then distinguish HIT from hemodilu-
tion or other causes of thrombocyto-
penia, we also categorize the patterns
of platelet counts as outlined by Pou-
plard and colleagues.4
Our standardization of detection
methods did not alter the number of
patients who received a diagnosis of
HIT (14.5% compared with 15.1%
before 2007). However, we did see
an increased rate in the use of
bivalirudin to treat thrombocytopenia
(23.1% compared with 17.5%)
(Table 1). This suggests that our stan-
dardization procedures may have re-
sulted in earlier identification and
medical management of HIT.ry c Volume 145, Number 1 311
Letters to the EditorInterestingly, whereas there did not
appear to be a difference in the inci-
dence of HIT and thrombosis syn-
drome (HITTS), we did find that
mortality owing to HITTS decreased
from 60.0% to 23.0% after altering
our HIT detection and treatment pro-
cedures (Table 1). Together, these
findings suggest that the standardiza-
tion of the methods for earlier identifi-
cation and management of HIT with
bivalirudin improved the mortality
rate among patients diagnosed with
HIT after cardiac surgery.
The article byDemma, Paciullo, and
Levy1 has made an important contribu-
tion by raising awareness of methods
used to identify and treat HIT with ar-
gatroban in patients who have had car-
diac surgery. Combined with our
aforementioned findings using bivalir-
udin, we can conclude that the early
detection andmanagement of thrombo-
cytopenia with DTIs in the patient who
has had cardiac surgery is an important
clinical consideration in improving pa-
tient outcomes.
Robert Kramer, MD
Crystal Herron, PhD
Division of Cardiothoracic Surgery
Maine Medical Center
Portland, Maine
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CATHETERIZATION WITH
ACUTEKIDNEY INJURY IN THE
CARDIAC SURGICAL PATIENT
To the Editor:
In a recent publication, Andersen
and colleagues1 concluded that cardiac
catheterization within 1 to 3 days be-
fore proximal aortic surgery is not asso-
ciatedwith an increase in postoperative
acute kidney injury (AKI). Although
our own interest in the occurrence and
duration of AKI has lain primarily
with patients undergoing coronary
artery bypass grafting,2,3 we are
conscious of special circumstances in
which the postoperative AKI rate does
not appear to be affected, such as for
same-day cardiac catheterization and
aortic valve surgery.4 Despite our
knowledge of these special circum-
stances, we wish to caution readers to
pay close attention to the limitations
of the study by Andersen and col-
leagues,1 limitations that they them-
selves have clearly detailed in their
article but have not reflected in their
title.
Of particular interest are the effects
of contrast media on AKI in cardiac
surgical patients. In their analysis, An-
dersen and colleagues1 demonstrated
that patients who received contrast
media within 3 days before proximal
aorta surgery actually had a lower
rate of postoperative AKI than did pa-
tients whowere exposed between days
4 and 54 before the operation. In con-
trast, we have recently demonstrated
that the incidence of postoperative
AKI was significantly increased
when cardiac catheterization was con-
ducted within the same hospital ad-
mission as cardiac surgery.2
Although we do not have direct evi-
dence to support a role for contrast
media in the occurrence of AKI in
this model, a previously published
study has shown that exposure to con-
trast media may augment necrosis and
renal tubular cell apoptosis.5 We
therefore agree with Andersen and
colleagues1 regarding the importanceardiovascular Surgery c January 2013of careful preoperative evaluation of
the risks of contrast exposure in the
cardiac surgical patient.
Fortunately, Andersen and col-
leagues1 were thorough in emphasiz-
ing the limitations of their findings,
in that they discussed the possibility
that variability between groups could
have confounded their results. Specif-
ically, the outcomes may have been
influenced by the presence of known
risk factors for AKI in the long-
interval catheterization group, such
as age, body mass index, and conges-
tive heart failure. In addition, Ander-
sen and colleagues1 discussed
differences in the catheterization pro-
tocols, noting the limited use of con-
trast media and increased
intravenous hydration in the short-
interval catheterization group relative
to the long-interval group. These dif-
ferences could have affected the sig-
nificance of their findings, and we
therefore believe that additional,
well-designed studies are needed for
further delineation of the ideal time
frame between catheterization and
surgery.
Although there are strong motiva-
tions for reducing the time between
cardiac catheterization and surgery,
such as reducing hospital costs, pa-
tient inconvenience, and physician
anxiety about a potentially life-
threatening disease, the long-term
implications of postoperative AKI
with respect to reduced patient sur-
vival remain of the utmost concern.3
The article of Andersen and col-
leagues1 provides interesting insights
into the management of patients be-
tween catheterization and cardiac
surgery; however, the confounding
factors in their study encourage the
development of further investigations
to delineate the exact time needed
between contrast media exposure
and the initiation of cardiac surgery.
Future studies of this nature may
aid in determining the best methods
to ensure the lowest possible risk of
AKI and provide the best chance for
